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Abstract 
 
The contribution of fungal infections to the morbidity and mortality of HIV-infected 
individuals is largely unrecognized. A recent meeting highlighted several priorities 
that need to be urgently addressed, including improved epidemiological surveillance, 
increased availability of existing diagnostics and drugs, more training in the field of 
medical mycology and better funding for research and provision of treatment, 
particularly in developing countries.   
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Fungi are often harmless in the context of normal host responses, but immune 
deficiencies, particularly in HIV-positive patients, result in significantly increased 
susceptibility to many fungal infections. The global defects in immune function 
resulting from HIV infection, in particular, causes susceptibility to several mucosal 
and life-threatening fungal diseases with pathogens such as Candida, Cryptococcus 
and Pneumocystis. For example, it has been estimated that HIV/AIDS results in 
nearly 10 million cases of oral thrush and 2 million cases of oesophageal fungal 
infections annually [1, 2]. Of even greater concern is the high mortality associated 
with invasive fungal infections, which often exceeds 50%, despite the availability of 
antifungal drugs [2]. For example, the U.S. Centers for Disease Control and 
Prevention (CDC) have estimated that there are approximately one million cases of 
cryptococcal meningitis globally every year in patients with HIV/AIDS with over 
500,000 related deaths in sub-Saharan Africa in 2008 [3]. Although the accuracy of 
mortality estimates may be questionable, it is likely that fungal infections collectively 
kill about one and a half million people every year [1, 2]. Thus, it is possible that at 
least as many people die from fungal diseases as tuberculosis (see 
http://www.who.int/mediacentre/factsheets/fs104/en/) or malaria (see 
http://www.who.int/mediacentre/factsheets/fs094/en/). Despite the huge burden and 
high mortality rates of fungal infections in HIV-infected patients these diseases 
remain understudied and underdiagnosed compared with other infectious diseases 
[1, 2]. 
To address this burgeoning problem, over 80 participants from all over the 
world gathered for three days in July 2013 in Cape Town, South Africa, for a meeting 
on AIDS-related mycoses (Figure 1). Plenary presentations at this conference 
covered topics including; the effect of HIV/AIDS on antifungal immunity; current 
limitations in diagnosis of these infections (particularly Pneumocystis in resource-
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limited settings); the epidemiology, surveillance and public health aspects of these 
infections; the pathogenesis of fungal diseases (both from the host and pathogen 
perspective, including sessions on Candida, Pneumocystis, Cryptococcus and other 
fungi); pathogenesis of fungal-related immune reconstitution inflammatory syndrome; 
and treatment options and the way forward (see the corresponding review [4] in this 
issue for more details on each of these topics). Considerable time was given to goal-
directed general discussion during this meeting and six priorities for the immediate 
future were reached by consensus of all participants. These include: 
 
1. Better epidemiological surveillance is needed, as accurate estimates are 
unavailable for invasive fungal infections in HIV-infected patients globally. 
 
2. There is a pressing need for better laboratory and point-of-care diagnostics 
and better availability of existing diagnostics for many fungal diseases. This is 
particularly true for Pneumocystis jirovecii pneumonia, for which the 
diagnostics available have limited sensitivity and availability (see 
www.gaffi.org/wp-content/uploads/Pneumocystis-pneumonia-Fact-Sheet.pdf). 
Diagnostics need to be inexpensive, accessible and simple for use in 
developing countries, such as the dipstick immunochromatographic test 
currently in use for the diagnosis of cryptococcal meningitis and for screening 
for antigenaemia prior to the development of meningitis. Better diagnostics 
would facilitate aim (1).  
 
3. We need better availability of existing drugs, particularly for Cryptococcus. 
Initial combination therapy with amphotericin B and flucytosine was recently 
shown to improve outcomes for cryptococcal meningitis [5], yet these drugs 
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(especially flucytosine) are not readily available in many low and middle-
income countries, particularly in Africa, where there are high rates of mortality. 
These drugs need to be administered in combination for 2 weeks followed by 
fluconazole consolidation therapy. Antiretroviral therapy (ART) should be 
started 4-6 weeks after commencing antifungal therapy, to minimize the risk of 
mortality observed in recent trials of early introduction of ART [5]. 
 
4. More training in medical mycology (detection, diagnosis and treatment) is 
needed, particularly in resource-limited settings where expertise and facilities 
for fungal identification are lacking. Access to relevant equipment is also 
required. An example is the benefit in reducing intracranial pressure during 
cryptococcal meningitis by serial lumbar puncture, yet the equipment required 
to measure intracranial pressure, e.g. a simple manometer, and relevant 
training in its use are lacking in most developing countries where this disease 
is endemic. 
  
5. We need to stimulate funding in this area. Despite the high global burden of 
invasive mycoses, only 2% -2.5% of infectious disease research budgets of 
the major funders in the UK and USA are targeted at human fungal infections 
[2]. There is an urgent need, in particular, for funding to implement programs 
aimed at better diagnosis, treatment and surveillance of cryptococcosis in sub-
Saharan Africa. Such programs could save tens of thousands of lives annually 
(see Box 1). In addition to lobbying traditional funding agencies, we propose 
to: 
i. Approach private philanthropic foundations.  
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ii. Submit a multi-European group application that focuses on 
critical issues in fungal diseases encountered in the developed 
and developing world.  
 
6. We propose to maintain momentum within this field by establishing a working 
group on AIDS-related mycoses under the International Society for Human 
and Animal Mycology (ISHAM), hold a working group meeting at the ISHAM 
meeting in Melbourne in May 2015, and convene a second workshop on 
AIDS-related mycoses in Cape Town in 2016. 
 
Fungal infections represent a major threat to individuals infected with HIV, particularly 
in developing counties. Greater funding and implementation of the approaches 
described here would have a significant impact and lead to substantial reductions in 
the morbidity and mortality associated with these diseases.  
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Figure 1. Participants of the EMBO-workshop on AIDS-related mycoses held in July 
2013 at the Institute of Infectious Disease and Molecular Medicine, University of 
Cape Town, South Africa.  
